Treatment with I3C has demonstrated efficacy in treating patients with IBD, partially through the upregulation of IL-22, suggesting that targeting AhR could be a strategy to modulate the magnitude and duration of IL-22 signaling for the treatment of IBD patients, as well as I3C is being investigated as a natural therapeutic option for IBD. This evidence concerns the gene IL22 and inflammatory bowel disease.